转移性黑色素瘤新辅助治疗后切除标本的病理评估
国际新辅助黑色素瘤联盟(INMC)在2016和2017年会议上汇集病理学家,针对AJCC第8版IIIB/C/D期或寡转移IV期黑色素瘤患者,制定新辅助靶向或免疫治疗后手术标本病理检查与报告的共识指南。指南提供标本处理流程、病理反应定义与分级标准,并描述新辅助靶向治疗和免疫检查点治疗后观察到的组织病理反应谱系,旨在标准化评估以更好地分层患者预后并促进临床试验间比较。
要点
- 新辅助治疗后黑色素瘤切除标本的病理评估需标准化处理与报告流程。
- 共识提供了病理反应的定义、报告规范及反应程度量化分级方法。
- 需识别新辅助靶向或免疫治疗后组织病理反应谱系以指导预后分层。
核心结论
- 标准化新辅助靶向或免疫检查点治疗后切除黑色素瘤转移灶的病理评估,可更可靠地分层患者结局。
- 标准化评估包括识别组织病理反应谱系和采用统一的病理反应分级方法,有助于跨临床试验比较结果并支持相关性研究。
研究设计与样本
- 国际新辅助黑色素瘤联盟(INMC)于2016和2017年召开会议,汇集学术中心病理学家制定共识指南。
- 指南针对AJCC第8版IIIB/C/D期或寡转移IV期黑色素瘤患者,接受新辅助靶向或免疫治疗后的手术标本。
主要发现
- 基于集体经验并参照乳腺癌等成熟新辅助治疗领域的实践,提供了新辅助治疗前后黑色素瘤标本的处理流程。
- 提供了病理反应的定义以及报告和量化病理反应程度的指南。
- 描述并图示了新辅助靶向治疗和免疫检查点治疗后观察到的组织病理反应谱系。
关键数值与推荐
- 病理反应定义、报告规范及反应程度量化方法已提供,具体数值原文未报告。
- 标本处理流程旨在促进不同试验和中心间研究结果的比较。
临床怎么用
- 病理科医生应按共识流程处理新辅助治疗后黑色素瘤切除标本,并规范报告病理反应类型与程度。
- 临床团队可依据标准化病理反应评估进行预后分层,并支持跨试验结果比较。
局限性
- 原文未报告指南基于的循证等级或外部验证数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Clinical trials have recently evaluated safety and efficacy of neoadjuvant therapy among patients with surgically resectable regional melanoma metastases. To capture informative prognostic data connected to pathological response in such trials, it is critical to standardize pathologic assessment and reporting of tumor response after this treatment. METHODS: The International Neoadjuvant Melanoma Consortium meetings in 2016 and 2017 assembled pathologists from academic centers to develop consensus guidelines for pathologic examination and reporting of surgical specimens from AJCC (8th edition) stage IIIB/C/D or oligometastatic stage IV melanoma patients treated with neoadjuvant-targeted or immune therapy. Patterns of pathologic response are provided context to inform these guidelines. RESULTS: Based on our collective experience and guided by efforts in well-established neoadjuvant settings like breast cancer, procedures directing handling of pre- and post-neoadjuvant therapy-treated melanoma specimens are provided to facilitate comparison of findings across different trials and centers. Definitions of pathologic response are provided together with guidelines for reporting and quantifying the extent of pathologic response. Finally, the spectrum of histopathologic responses observed following neoadjuvant-targeted and immune-checkpoint therapy is described and illustrated. CONCLUSIONS: Standardizing pathologic evaluation of resected melanoma metastases following neoadjuvant-targeted or immune-checkpoint therapy allows more robust stratification of patient outcomes. This includes recognizing the spectrum of histopathologic response patterns to neoadjuvant therapy and a standard approach to grading pathologic responses. Such an approach will facilitate comparison of results across clinical trials and inform ongoing correlative studies into the mechanisms of response and resistance to agents applied in the neoadjuvant setting.
引用
- Tetzlaff MT, Messina JL, Stein JE, et al. Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma. Ann Oncol. 2018. PMID: 29945191. doi:10.1093/annonc/mdy226
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。